Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy‐naive metastatic castration‐resistant prostate cancer

Dong, Baijun; Fan, Liancheng; Wang, Yanqing; Chi, Chenfei; Ma, Xiaowei; Wang, Rui; Cui, Wen; Shao, Xiaoliang; Pan, Jiahua; Zhu, Yao; Shangguan, Xun; Zheng, Xiaoyang; Hu, Jianian; Xie, Songqiang; Kang, Xiaonan; Zhou, Lixin; Xue, Wei

doi:10.1002/pros.23397

Cited by 19 publications

(30 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because the most widely used routine prognostic assessment of mCRPC currently still relies on traditional clinicopathological prognostic variables including the type and duration of prior therapy, LDH and NLR, recent advance in the identification of molecular and genetic alterations in mCRPC has been made . In spite of these biomarkers enhancing the predictive accuracy of prognostic model, the high costs of analysis, the time‐consuming preparation and the lack of evidence together prevent them into clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

In this study, we did not observe differences in clinical outcomes based on alternative sequencing of AA and DP in mCRPC patients. The ability to tolerate side effects and patient preference may be used to determine the treatment sequencing. In addition, high pretreatment SII level is a negative independent prognosticator of survival outcomes in mCRPC with sequential therapy using DP followed by AA or vice versa, which might guide clinicians select the best treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Table 1 summarizes the main features and findings of the included studies. 14 15 22 23 24 25 26 27 The CRPC patients were from different countries (Italy, America, Germany, and China). The study publication time ranged from 2000 to 2017.…”

Section: Resultsmentioning

confidence: 99%

“…The study publication time ranged from 2000 to 2017. For the eight eligible studies, six studies 14 15 22 23 24 25 containing 599 patients were carried out to research the influence of CgA level on the OS of CRPC patients, two studies 22 23 containing 83 patients investigated the PFS, and two studies 26 27 including 53 patients were used to research the influence of CgA changes on the PFS of CRPC patients. The quality scores of the included studies ranged from 7 to 9, and these studies are qualified for meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis

et al. 2018

View full text Add to dashboard Cite

We aimed to investigate the prognostic value of chromogranin A (CgA) in castration-resistant prostate cancer (CRPC). We conducted a systematic literature search of PubMed, Web of Science, and EMBASE for citations published prior to September 2017 that described CgA and CRPC and performed a standard meta-analysis on survival outcomes. Our meta-analysis included eight eligible studies with 686 patients. The results were as follows: progression-free survival (PFS) was associated with CgA level (hazard ratio [HR] = 2.47, 95% confidence interval [CI]: 1.47–4.14, P = 0.0006); PFS was relative to CgA change (HR = 9.22, 95% CI: 3.03–28.05, P < 0.0001); and overall survival (OS) was relative to CgA level (HR = 1.47, 95% CI: 1.15–1.87, P = 0.002). When we divided the patients into two groups according to therapy status, the result for OS relative to CgA level was an HR of 1.26 (95% CI: 1.09–1.45, P = 0.001) in the first-line hormonal therapy group, and an HR of 2.33 (95% CI: 1.40–3.89, P = 0.001) in the second-line hormonal therapy or chemotherapy group. This meta-analysis indicated that a high CgA level had a negative influence on OS and PFS in CRPC patients. In addition, CRPC patients with a rising CgA had a shorter PFS. Further studies are needed to verify the prognostic value of CgA in CRPC.

show abstract

“…Almost all of these studies show an overall increase in expression of these resistance markers at progression. However, studies that focused on whether abiraterone was specifically associated with increased expression of some of these neuroendocrine markers, in particular, have not identified an association specifically with abiraterone . Another study looking at lifetime risk of development of visceral metastases did not identify an association with prior treatment with abiraterone or enzalutamide with the development of visceral metastases .…”

Section: Discussionmentioning

confidence: 99%

Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU‐AA‐302

et al. 2019

View full text Add to dashboard Cite

Background: Abiraterone increases survival in prostate cancer, but tumors resistant to abiraterone can exhibit a hormonally resistant, aggressive phenotype. We hypothesized that the therapeutic pressure of abiraterone is resulting in more clinically aggressive disease at progression, characterized by increased visceral metastases. Our objective was to determine whether abiraterone increased the risk of development of visceral metastases at the time of progression compared with placebo in a randomized phase III trial. Methods: We performed a post hoc analysis of the COU-AA-302 trial of abiraterone plus prednisone vs placebo plus prednisone in patients with metastatic castrationresistant prostate cancer. The primary outcome was the development of visceral metastases. The cumulative incidences of visceral metastases were calculated by the Kaplan-Meier method and compared using log-rank testing. Multivariable Cox regression analysis assessed for the independent association of abiraterone with the development of visceral metastases.Results: Eighty-four of 1088 patients developed visceral metastases during study.Log-rank testing and Cox regression showed no difference in time to visceral metastases between groups (HR 1.01 [95% confidence interval (CI), 0.65-1.56]; P = .97). Abiraterone treatment was not associated with the development of visceral metastases in multivariable analysis (HR 0.89 [95% CI, 0.57-1.40]; P = .62). The study was limited by censoring of radiographic outcomes at the time of completion of primary study therapy; longer term risks were not assessed. Conclusions:Abiraterone was not associated with increased risk of visceral metastatic disease at the time of progression compared with placebo.

show abstract

Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy‐naive metastatic castration‐resistant prostate cancer

Cited by 19 publications

References 31 publications

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis

Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU‐AA‐302

Contact Info

Product

Resources

About